The coronavirus pandemic brings home the importance of raising the rates at which American adults are immunized with the yearly influenza vaccine, as well as with other high-priority vaccines recommended by the CDC’s Advisory Committee on Immunization Practices (ACIP). The importance of maintaining the health of our general population, and especially of adults with health risks, cannot be overstated. COVID-19 makes this truth unavoidable.
Encouraging progress has been made in the last decade. Insurance coverage of adult immunizations is better for many patients. Community pharmacists play an ever-growing role as immunizers providing greater access. Adult immunization rates have ticked up over the last decade. But progress remains incremental and, as our findings make clear, immunization policy remains a patchwork. Among other things, out-of-pocket cost obligations for patients varies from one type of insurance coverage to another. Immunization authority for pharmacists and other community-based immunizers is inconsistent from state to state. Payment incentives for raising adult immunization rates are misaligned among payers, hospital systems and physician offices, and community-based immunizers such as pharmacists.
We cannot avoid the COVID-19 virus now. But we may be able to do so in the future, and certainly we may be able to minimize hospitalizations and the other adverse consequences of influenza IF we recognize that fixing our immunization policies is an urgent task.
NEHI recommends action in four areas:
- Affordability: Harmonize coverage policy across public and private sector health insurance plans to lower or eliminate out-of-pocket costs to adult immunization;
- Access: Harmonize scope-of-practice regulation so that community-based immunizers, such as pharmacists, have similar immunizing authority in all communities and in all states. Always make immunization with ACIP-recommended vaccines an “always in-network” service;
- Information: Align reporting standards for state immunization information systems—and secure public investments in these-- so that they provide all authorized immunizers with accurate patient immunization histories and allow all authorized immunizers to see immunization histories in real time;
- Innovation: Incentivize investments to scale innovative models of patient screening, referral and immunization to reach adults who have not received recommended immunizations.
Adult immunization – one of the most highly effective of evidence-based services – must be a high priority. These recommendations will require effort and careful consideration of, among other things, how increased costs should be apportioned between health insurance plans and other sources of public and private payment. Nevertheless, we have solved far greater challenges. We cannot continue to push this issue into the future.
NEHI’s analysis is an outgrowth of discussions it generated among leading patient advocates, clinicians, health insurance leaders, biopharma experts, and others. For more information, please contact Tom Hubbard, NEHI Vice President of Policy Research, at email@example.com.